All In Biotech

Drug Trial Radar · NCT01909453

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 921 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

921

Actual

Start

Sep 12, 2013

Primary completion

Nov 9, 2016

Study completion Sep 3, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized. Part 1: Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms: 1. LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm) 2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or 3. vemurafenib 960 mg BID (denoted as vemurafenib arm) Part 2: Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms: 1. LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or 2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm)

Conditions

  • Melanoma

Interventions

  • LGX818Drug

    LGX818- Orally 100 mg and 50 mg capsules

  • MEK162Drug

    MEK162- Orally 15 mg tablets

  • vemurafenibDrug

    Tablets in bottles or blisters 240 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib GroupTime frame: From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months)
  2. Part 1: PFS by BIRC in Combo 450 Group as Compared to LGX818 GroupTime frame: From randomization until documented PD, initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months), excluding Part 1: LGX818 300 mg group; up to 35 months for Part 1: LGX 300 mg group

Locations

282 sites in 29 countries. Site status is shown where the registry gives one.

  • Retinal Consultants of Alabama P.C.

    Birmingham, Alabama

  • UAB Callahan Eye Hospital

    Birmingham, Alabama

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • UAB The Kirklin Clinic

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Oncology Associates

    Tucson, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Rogers, Arkansas

  • Highlands Oncology Group - Fayetteville

    Springdale, Arkansas

  • UC Irvine Medical Center

    Orange, California

  • Rocky Mountain Cancer Centers (Williams) - USOR

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Boulder, Colorado

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers (Williams) - USOR

    Denver, Colorado

  • Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Specialty Eye Care

    Parker, Colorado

  • Rocky Mountain Cancer Centers

    Pueblo, Colorado

  • University Cancer Institute

    Boynton Beach, Florida

  • University of Miami

    Miami, Florida

  • Eye & Ear Infirmary- Opthalmology

    Chicago, Illinois

  • University of Illinois at Chicago

    Chicago, Illinois

  • University of Illinois Hospital and Health Sciences System - Investigational Drug Service

    Chicago, Illinois

  • University of Illinois Hospital and Health Sciences System

    Chicago, Illinois

  • University of Illinois Medical Center

    Chicago, Illinois

  • Oncology Specialists, SC

    Niles, Illinois

  • Goshen Center For Cancer Care

    Goshen, Indiana

  • Lack's Cancer Center at Mercy Health Saint Mary's

    Grand Rapids, Michigan

  • Mercy Health Hauenstein Neuroscience Center Neuro-Ophthalmology (Clinic)

    Grand Rapids, Michigan

  • Retina Specialists of Michigan

    Grand Rapids, Michigan

  • Hattiesburg Clinic Oncology Hem

    Hattiesburg, Mississippi

  • Jackson Oncology Associates - St. Dominic Hospital

    Jackson, Mississippi

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Investigational Drug Service, Department of Pharmacy (Investigational Product)

    Rochester, New York

  • University of Rochester Medical Center - PPDS

    Rochester, New York

  • Tulsa Cancer Institute PLLC

    Tulsa, Oklahoma

  • University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania

  • Sanford Cancer Center Oncology Clinic & Pharmacy

    Sioux Falls, South Dakota

  • University of Tennessee Medical Center Cancer Institute

    Knoxville, Tennessee

Showing 40 of 282 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.